What is Insitro?
Insitro is at the forefront of revolutionizing drug development by integrating advanced machine learning techniques with comprehensive biological data. The company's core mission is to decode the complexities of human biology to bring better and faster treatments to patients. By analyzing vast datasets that combine in vitro cellular data with human clinical information, Insitro aims to redefine disease understanding and identify novel therapeutic targets. Their multidisciplinary team of life scientists, data scientists, and engineers is dedicated to building a robust pipeline across critical therapeutic areas, including metabolism, oncology, and neuroscience, positioning them as a key player in the biopharmaceutical innovation landscape.
How much funding has Insitro raised?
Insitro has raised a total of $643M across 3 funding rounds:
Series A
$100M
Series B
$143M
Series C
$400M
Series A (2019): $100M with participation from ARCH VENTURE PARTNERS, Verily, Two Sigma Ventures, Bezos Expeditions, Mubadala, GV, Foresite Capital, and Third Rock Ventures
Series B (2020): $143M led by Andreessen Horowitz, HOF Capital, BlackRock, Casdin Capital, CPP Investments, T. Rowe Price Associates, and WuXi AppTec
Series C (2021): $400M supported by BlackRock, T. Rowe Price Associates, Third Rock Ventures, Foresite Capital, ARCH VENTURE PARTNERS, GV, HOF Capital, Two Sigma Ventures, CPP Investments, Alexandria Venture Investments, Casdin Capital, and Andreessen Horowitz
Key Investors in Insitro
BlackRock
BlackRock is a global investment management firm offering a comprehensive range of investment products and services, including mutual funds and ETFs, and provides investment management, risk management, and advisory services to institutional and individual investors.
T. Rowe Price Associates
T. Rowe Price Group is an investment firm that manages equity and fixed income mutual funds, serving individuals, institutional investors, and retirement plans with a global investment strategy.
Third Rock Ventures
Third Rock Ventures is a healthcare venture firm focused on launching and building companies in disruptive areas of science and medicine, leveraging scientific vision and operational expertise to create value for patients.
What's next for Insitro?
With the recent infusion of $400M in a major strategic investment, Insitro is well-positioned to further scale its operations and accelerate its drug discovery and development programs. This enterprise-level funding suggests a focus on expanding its research capabilities, advancing its therapeutic pipeline through clinical trials, and potentially forging new strategic partnerships. The company's commitment to data-driven biology and machine learning indicates a strategic direction towards optimizing the efficiency and success rates of bringing novel therapies to market, solidifying its role as an innovator in the biopharmaceutical sector.
See full Insitro company page
